NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma

NCT07200375

RecruitingN/A

Sponsor: Hoffmann-La Roche

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Glofitamab

Countries: China, Hong Kong

This study will investigate how well glofitamab-based therapy works and how safe it is in Chinese adult participants with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Histologically confirmed R/R DLBCL after one line of systemic therapy
* Will be treated with Glofit-based regimen (known as being recommended and having the intention to be treated with Glofitamab at the time of signing ICF) or have initiated Glofit-based regimen treatment within three months (90 days) prior to enrollment

Exclusion Criteria:

* Participants who currently participate in or plan to participate in any interventional clinical trial

Locations (21)

Langfang, Hebei, China
Tianjin, Tianjin Municipality, China
Beijing, China
Beijing, China
Changchun, China
Chengdu, China
Guangzhou, China
Harbin, China
Jinan, China
Nanchang, China
Ningbo, China
Shanghai, China
Shanghai, China
Tianjin, China
Wenzhou, China
Wuhan, China
Wuhan, China
Xi'an, China
Yantai, China
Zhengzhou, China
Hong Kong, Hong Kong